An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era-Reference-Cited by-同舟云学术

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Published:2014-02-06 Issue:6 Volume:123 Page:837-842
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zhou Zheng¹,Sehn Laurie H.²,Rademaker Alfred W.¹,Gordon Leo I.¹,LaCasce Ann S.³,Crosby-Thompson Allison³,Vanderplas Ann⁴,Zelenetz Andrew D.⁵,Abel Gregory A.³,Rodriguez Maria A.⁶,Nademanee Auayporn⁷,Kaminski Mark S.⁸,Czuczman Myron S.⁹,Millenson Michael¹⁰,Niland Joyce⁴,Gascoyne Randy D.²,Connors Joseph M.²,Friedberg Jonathan W.¹¹,Winter Jane N.¹

Affiliation:

1. Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL;

2. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;

3. Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;

4. Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, CA;

5. Medicine/Lymphoma, Memorial Sloan-Kettering Cancer Center, New York, NY;

6. Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX;

7. Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, CA;

8. University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;

9. Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY;

10. Fox Chase Cancer Center, Philadelphia, PA; and

11. James P. Wilmot Cancer Center, University of Rochester, Rochester, NY

Abstract

Key Points The clinically based NCCN-IPI is a robust prognostic tool for the rituximab era that better discriminates low- and high-risk DLBCL patients compared with the IPI. The NCCN-IPI outperforms the IPI by refined categorization of age and LDH, and the identification of disease involvement at specific extranodal sites.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/6/837/1378523/837.pdf

Reference28 articles.

1. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project.;N Engl J Med,1993

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.;Coiffier;N Engl J Med,2002

3. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.;Habermann;J Clin Oncol,2006

4. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.;Ziepert;J Clin Oncol,2010

5. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.;Sehn;Blood,2007

Cited by 659 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma;Blood Advances;2024-02-13

2. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma;Transplantation and Cellular Therapy;2024-02

3. The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline;British Journal of Haematology;2024-01-21

4. Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials;Leukemia & Lymphoma;2024-01-05

5. Prognostic value of 18F-FDG PET/CT tumor metabolic parameters and Ki-67 in pre-treatment diffuse large B-cell lymphoma;Quantitative Imaging in Medicine and Surgery;2024-01